PRIMAXIN

This brand name is authorized in Canada, Ireland, Malta, United Kingdom, United States

Active ingredients

The drug PRIMAXIN contains a combination of these active pharmaceutical ingredients (APIs):

1 Imipemide UNII 71OTZ9ZE0A - IMIPENEM

Imipenem is a semi-synthetic derivative of thienamycin, the parent compound produced by the filamentous bacterium Streptomyces cattleya. Imipenem exerts its bactericidal activity by inhibiting bacterial cell wall synthesis in Gram-positive and Gram-negative bacteria through binding to penicillin-binding proteins (PBPs). Read about Imipemide

2 Cilastatin UNII 5428WXZ74M - CILASTATIN SODIUM

Read about Cilastatin

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
PRIMAXIN IV Powder for solution for infusion	Medicines & Healthcare Products Regulatory Agency (GB)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
J01DH51	Imipenem and enzyme inhibitor	J Antiinfectives for systemic use → J01 Antibacterials for systemic use → J01D Other beta-lactam antibacterials → J01DH Carbapenems
Discover more medicines within J01DH51

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: CA	Health Products and Food Branch	Identifier(s): 00717282
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 43919
Country: MT	Medicines Authority	Identifier(s): AA565/59501
Country: US	FDA, National Drug Code	Identifier(s): 0006-3516